Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay–Sachs Disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Tay–Sachs disease (TSD) is a fatal neurodegenerative disorder caused by a deficiency of the enzyme hexosaminidase A (HexA). TSD also occurs in sheep, the only experimental model of TSD that has clinical signs of disease. The natural history of sheep TSD was characterized using serial neurological evaluations, 7 Tesla magnetic resonance imaging, echocardiograms, electrodiagnostics, and cerebrospinal fluid biomarkers. Intracranial gene therapy was also tested using AAVrh8 monocistronic vectors encoding the α-subunit of Hex (TSD α) or a mixture of two vectors encoding both the α and β subunits separately (TSD α + β) injected at high (1.3 × 1013 vector genomes) or low (4.2 × 1012 vector genomes) dose. Delay of symptom onset and/or reduction of acquired symptoms were noted in all adeno-associated virus–treated sheep. Postmortem evaluation showed superior HexA and vector genome distribution in the brain of TSD α + β sheep compared to TSD α sheep, but spinal cord distribution was low in all groups. Isozyme analysis showed superior HexA formation after treatment with both vectors (TSD α + β), and ganglioside clearance was most widespread in the TSD α + β high-dose sheep. Microglial activation and proliferation in TSD sheep—most prominent in the cerebrum—were attenuated after gene therapy. This report demonstrates therapeutic efficacy for TSD in the sheep brain, which is on the same order of magnitude as a child's brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Sango, K., Yamanaka, S., Hoffmann, A., Okuda, Y., Grinberg, A., Westphal, H., McDonald, M. P., Crawley, J. N., Sandhoff, K., Suzuki, K., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-170 · Cited by 468 · cited 1×
“4,8 First reported in 2010, the sheep TSD model is caused by a point mutation at the end of exon 11, resulting in a reduction of HexA activity to * 6% of normal in the brain.”
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66778 · Cited by 215
Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1 H-MRS at 0.5 T
Antuono, P. G., Jones, J. L., Wang, Y., & Li, S.-J. (2001) · Neurology · doi:10.1212/wnl.56.6.737 · Cited by 119
AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement
Golebiowski, D., Bradbury, A. M., Kwon, C.-S., van der Bom, I. M. J., Stoica, L., Johnson, A. K., Wilson, D. U., Gray-Edwards, H. L., Hudson, J. A., Johnson, J. A., et al. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_11 · Cited by 6
Self-citation
Cited by
Keeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
AAV gene therapy for Tay-Sachs disease
Flotte, T. R., Cataltepe, O., Puri, A., Batista, A. R., Moser, R., McKenna-Yasek, D., Douthwright, C., Gernoux, G., Blackwood, M., Mueller, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01664-4 · Cited by 143
Self-citationGene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
“Further, bi-thalamic AAVrh.8-mediated gene therapy in a sheep model of TSD [173,174] was comparably effective [175,176].”
Background
Metadata
- Authors
- Gray-Edwards, H. L., Randle, A. N., Maitland, S. A., Benatti, H. R., Hubbard, S. M., Canning, P. F., Vogel, M. B., Brunson, B. L., Hwang, M., Ellis, L. E., Bradbury, A. M., Gentry, A. S., Taylor, A. R., Wooldridge, A. A., Wilhite, D. R., Winter, R. L., Whitlock, B. K., Johnson, J. A., Holland, M., Salibi, N., Beyers, R. J., Sartin, J. L., Denney, T. S., Cox, N. R., Sena-Esteves, M., & Martin, D. R.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2018-03
- Volume
- 29
- Issue
- 3
- Pages
- 312-326
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2767326544
- Cited by
- 96
- References
- 6
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay–Sachs Disease. https://app.cochat.ai/papers/10.1089/hum.2017.163
- The paper
- Gray-Edwards, H. L., Randle, A. N., Maitland, S. A., Benatti, H. R., Hubbard, S. M., Canning, P. F., Vogel, M. B., Brunson, B. L., Hwang, M., Ellis, L. E., Bradbury, A. M., Gentry, A. S., Taylor, A. R., Wooldridge, A. A., Wilhite, D. R., Winter, R. L., Whitlock, B. K., Johnson, J. A., Holland, M., . . . Martin, D. R. (2018). Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay–Sachs Disease. Human Gene Therapy. https://doi.org/10.1089/hum.2017.163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.